---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-021835"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:25:13.282520+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix Q2 revenue falls 41% to $1.3M; net loss widens to $4.6M; cash $42.9M

## Summary
- Q2 2022 revenue $1.3M vs $2.2M in Q2 2021; decrease driven by no PUR1800 revenue offset by Cipla agreement for Pulmazole.
- Net loss of $4.6M ($1.36 per share) vs $3.9M ($1.37) in Q2 2021; wider loss on lower revenue.
- Cash and equivalents $42.9M at June 30, 2022; expects to fund operations into Q2 2024.
- PUR3100 Phase 1 study dosed 23 of 24 patients; top-line data expected Q4 2022.
- Pulmazole Phase 2b study start-up initiated; patient dosing on track for Q1 2023.

## SEC filing metadata
- accession: 0001493152-22-021835
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315222021835/0001493152-22-021835-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315222021835/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-021835
- JSON: https://secwatch.observer/filing/0001493152-22-021835.json
- Plain text: https://secwatch.observer/filing/0001493152-22-021835.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.